Dopo le cellule Carcik per la leucemia mieloide acuta, i ricercatori della Fondazione Tettamanti di Monza hanno messo a punto anche una versione della terapia per la leucemia linfoblastica acuta di tipo b.
With access to more data than ever before – including data from patient records, laboratory research and experiments, clinical studies and decentralised trials, and scientific publications – now is the time for the industry to modernise, become data-led and boost patient experience.
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumours.
Datopotamab deruxtecan is the first antibody drug conjugate to demonstrate statistically significant improvement in PFS over docetaxel in this setting of high unmet need.
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median PFS benefit, and was well tolerated in post-endocrine therapy setting.
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients.
AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population.
Results reaffirm potential role of Enhertu as a tumour-agnostic therapy for previously treated patients with HER2-expressing solid tumours and support ongoing discussions with global regulatory authorities.
L'obiettivo principale di questo studio è quello di misurare i livelli di indicatori epigenetici (microRNA,metilazione di geni in celi-free DNA) in campioni longitudinali di biopsia liquida di pazienti affetti da tumori solidi. Questo per verificare le variazioni in risposta a trattamenti terapeutici e/o come indicatori di progressione di malattia.
AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population.
Results reaffirm potential role of Enhertu as a tumour-agnostic therapy for previously treated patients with HER2-expressing solid tumours and support ongoing discussions with global regulatory authorities.
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan plus Imfinzi showed a confirmed objective response rate of 79%. Two ongoing Phase III trials are evaluating datopotamab deruxtecan in patients with triple-negative breast cancer.
Transthyretin amyloidosis (ATTR) remains an underdiagnosed and underrecognised disease despite several guidelines available that inform its diagnosis and care. ATTR, which can show up in different forms, and its symptoms are commonly misattributed to other conditions. Patients with ATTR need a timely diagnosis and specialised plan to slow disease progression and improve their quality of life.
Preferences
Would you like to share some personal information with us so we can improve your experience on Researchalize.org?
